KRYS - Krystal Biotech to raise $100M in stock offering

Krystal Biotech (KRYS) commenced a $100M underwritten public offering; underwriters granted 30-day option to purchase an additional 15% of the shares.Offer size, terms have not been disclosed.Proceeds along with cash and short-term investments to be used for completing the ongoing pivotal trial of B-VEC for DEB and prepare for potential commercialization, advance the clinical development of KB105 in TGM1-deficient icthyosis and preclinical development of KB104 for Netherton syndrome and advance development of KB407 for cystic fibrosis

For further details see:

Krystal Biotech to raise $100M in stock offering